港股異動 | 先聲藥業漲8% 牽手Avilex Pharma引進急性缺血性腦卒中創新藥
格隆匯12月20日丨先聲藥業(2096.HK)現漲7.96%,報9.49港元,總市值249億港元。2021年12月15日,先聲藥業集團宣佈,與丹麥一家臨牀階段中樞神經新藥研發的生物技術公司Avilex Pharma達成區域戰略許可合作,引進一款靶向PSD-95的腦卒中創新藥AVLX-144在大中華地區(中國大陸,香港,澳門和台灣)對包括急性缺血性卒中(AIS)等急性病症在內所有適應症的開發、生產和商業化的權益。公司也同時獲授權使用Avilex開發的早期肽類候選分子庫。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.